Skip to content
NYSE · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP

Medtronic PLC MDT

14 fiscal years on record · USD · FY2025 reported · SEC filings only
11 YEARS OF DIVIDEND GROWTH
$36.4B
▲ 8.4% YoY
$4.8B
▲ 3.0% YoY
$5.4B
▲ 4.6% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Medtronic sells medical devices and therapies through a combination of direct sales representatives and third parties, such as independent distributors and agents, globally. It manufactures products at facilities located in various countries throughout the world. The company has over 95,000 full-time employees, of which 43% are based in the U.S. or Puerto Rico. It reports three segments: the Cardiovascular Portfolio, the Neuroscience Portfolio and the Medical Surgical Portfolio. The Cardiovascular Portfolio is made up of the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular divisions. The Neuroscience Portfolio is made up of the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. The Medical Surgical Portfolio includes the Surgical & Endoscopy and Acute Care & Monitoring divisions, whose products are used primarily by healthcare systems, physicians' offices, ambulatory surgical centers and other alternate site healthcare providers. Medtronic was founded in 1949 and serves healthcare systems, physicians, clinicians and patients in more than 150 countries worldwide.

Written from the business description in Medtronic plc's annual report to the U.S. Securities and Exchange Commission, filed 18 June 2026. Every sentence was checked against that document before publication.

Growth

USD 36.4B
Revenue, FY2025 · full 14-year series below
Revenue $B Net income $B
FY2025 · Revenue 36.4 · Net income 4.8
15B30B
201220152018202120242025
Compound annual growth
+5.2%
+3.8%
+2.3%
+8.5%
+5.9%
+3.1%
+9.8%
+7.0%
+4.2%
+1.4%
+4.1%
+6.5%
−0.8%
+2.0%
−1.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +3.8% a year over the five years to FY2025 — but profit grew faster: net income at +5.9%, earnings per share at +7.0%.

The share count fell from 1.35B to 1.28B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

13 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 17.8% · Net 13.3%
10%20%
201220182025
ROE
FY2025 · ROE 9.8%
5%10%15%
201220182025
Three returns, three denominators.

Each USD of equity produced 10 cents of profit this year.

Cash & shareholders

USD 4.2B
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 5.4
2.5B5.0B
201220182025
Net buybacks $B Dividends $B
FY2025 · Dividends 3.6 · Net buybacks 0.5
2.5B5.0BDividendsNet buybacks
20122014201620182020202220242025
Dividends paidUSD 3.6B
Net buybacksUSD 519.0M
Share of profit86.6%
Consecutive raises11 years (since the 2014 share-count change)

USD 3.6B in dividends and USD 519.0M in buybacks — 87% of the year's profit went back to shareholders.

Total assetsUSD 93.0B
EquityUSD 49.5B
CashUSD 1.9B
Gross debtUSD 28.0B
Net debtUSD 26.0B
Current ratio2.13×

Net debt stands at 53% of equity.

The 14-year record

14 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
MDT, 14-year financial record
Metric 20252024202320222021202020192018201720162015201420132012
Revenue $B36.433.532.431.231.730.128.930.630.029.728.820.317.016.6
Operating income $B6.56.05.15.55.84.54.86.36.65.45.43.83.84.4
EBITDA $B9.48.87.88.28.57.27.58.99.38.38.25.14.75.2
Income tax $B1.30.91.11.60.50.3−0.80.52.60.60.80.80.60.8
Net income $B4.84.73.73.85.03.64.84.63.14.03.52.73.13.5
Free cash flow $B5.45.25.24.66.04.96.05.93.65.64.24.34.64.5
EPS, diluted $3.733.612.762.823.732.663.543.412.272.892.482.413.023.37
Dividend / sh $2.842.802.762.722.522.322.162.001.841.721.521.221.121.04
Payout %76771009667876058805960503630
ROE %9.89.57.27.29.77.19.59.26.27.96.77.416.118.6
Shares out B1.281.281.311.331.331.351.341.341.351.371.401.421.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 59 reconciliationsAUDITED

Reconciled in 14 of the 14 fiscal years we could check. 12 checks were skipped: the balance sheet is not tagged before 2013. Five checks were skipped: EPS is not tagged before 2012. Five checks were skipped: revenue is not tagged before 2012.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNYSE
Incorporated innot stated in the filings
Fiscal year endsApril 24
Data on record since2012

Share this section

Download image